Hepatology Forum最新文献

{"title":"A new method for predicting alcohol relapse in patients undergoing liver transplantation for alcohol-related liver failure: Barratt scale.","authors":"Veysel Umman,&nbsp;Tufan Gumus,&nbsp;Ebubekir Korucuk,&nbsp;Recep Temel,&nbsp;Ozen Onen Sertoz,&nbsp;Fulya Gunsar,&nbsp;Alper Uguz,&nbsp;Murat Zeytunlu,&nbsp;Sukru Emre","doi":"10.14744/hf.2023.2023.0048","DOIUrl":"10.14744/hf.2023.2023.0048","url":null,"abstract":"<p><strong>Background and aim: </strong>Alcohol-induced liver disease has become one of the major causes of chronic liver disease worldwide with the increasing use of alcohol in society. The most important step in treatment is cessation of alcohol consumption. In patients with advanced liver disease, the most effective treatment is liver transplantation. Careful evaluation of patients with alcoholic liver disease before transplantation can help identify those at high risk of relapsing.</p><p><strong>Materials and methods: </strong>Of a total of 42 patients who underwent liver transplantation for alcohol-related liver failure in our hospital between 2011 and 2022, 26 surviving patients were included in the study. Patient data were analyzed retrospectively. Demographic data, MELD score, history of alcohol consumption, alcohol treatment, post-transplant prognosis and survival were analyzed. The Barratt Impulsivity Scale-11 Short Form (BIS-11 SF) was applied to the surviving patients for impulsivity analysis to predict the possibility of relapse.</p><p><strong>Results: </strong>Of the 26 patients who were included in the study, all were male. The mean age at transplantation was 53 (31-71) years. Mean MELD score was 22.31 (9-36). 12 patients (46.2%) received living donor liver transplantation and 14 patients (53.8%) received cadaveric liver transplantation. 25 patients (96.2%) had no post-transplant dependence, while 1 patient (3.8%) had post-transplant dependence. 5 patients (19.2%) continued to consume alcohol after transplantation.</p><p><strong>Conclusion: </strong>In our study, we observed that patients with high motor impulsivity tendency according to BSI-11 SF had alcohol relapse. We believe that revising this scale with more detailed questions for alcohol-dependent liver patients and applying it to patients before transplantation will be effective in better selection for transplantation and guiding patients to appropriate therapy and thus preventing relapse after transplantation.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/67/15/hf-4-118.PMC10564253.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41214608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practice patterns and considerations in liver transplantation from living donors with high BMI: A review.","authors":"Carl Samaha,&nbsp;Hadi Chaaban,&nbsp;Cem Simsek,&nbsp;Nilay Danis,&nbsp;Jessica S Lin,&nbsp;Ahmet Gurakar","doi":"10.14744/hf.2023.2023.0030","DOIUrl":"10.14744/hf.2023.2023.0030","url":null,"abstract":"<p><p>Living Donor Liver Transplantation (LDLT) is a valuable solution to the shortage of donor organs for patients with end-stage liver disease. However, the eligibility of obese donors for LDLT remains a subject of debate. This literature review explores global practices and perceptions of LDLT, identifies donor eligibility criteria, and discusses special considerations and ethical caveats. The review highlights the need for standardized guidelines for donor selection, considering the global distribution of Body mass index and variations in population-specific criteria. It also emphasizes the importance of non-invasive testing and pre-operative optimization of liver steatosis for select obese donors. Furthermore, the review examines the outcomes and complications associated with obese donors in LDLT. The findings of this review contribute to the ongoing discussion on the inclusion of obese donors in LDLT and provide insights for future research and guideline development.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/10/93/hf-4-145.PMC10564250.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41214613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental combined hepatocellular-cholangiocarcinoma in liver transplant patients: Does it have a worse prognosis?","authors":"Ender Anilir,&nbsp;Alihan Oral,&nbsp;Tolga Sahin,&nbsp;Fatih Turker,&nbsp;Yildiray Yuzer,&nbsp;Yaman Tokat","doi":"10.14744/hf.2022.2022.0037","DOIUrl":"https://doi.org/10.14744/hf.2022.2022.0037","url":null,"abstract":"<p><strong>Background and aim: </strong>Combined hepatocellular-cholangiocarcinoma (CHC) requires attention clinically and pathologically after liver transplantation (LT) because of its unique biology, difficulties in diagnosis, and being rare. We aimed to present our single-center experience for this incidental combined tumor. It is aimed to present our single-center experience for this incidental combined tumor.</p><p><strong>Materials and methods: </strong>Seventeen patients with CHC were included in the study. There were 260 hepatocellular carcinoma (HCC) patients determined as the control group. Patients were evaluated for demographic, etiological, pathological features, and survival.</p><p><strong>Results: </strong>Macrovascular and microvascular invasion levels were significantly higher in the CHC group (p<0.05). P53, CK19, and CK7 levels were significantly higher in the CHC group (p<0.05). Hepatocyte-specific antigen level was significantly higher in the HCC group. The mean overall survival was significantly higher in the HCC group (p<0.05).</p><p><strong>Conclusion: </strong>Even though CHC is a rare liver tumor, it has features that need to be clarified regarding both survival and tumor biology. İnvestigating prognostic factors, especially in terms of survival and recurrence, will be very beneficial to identify candidates who will benefit from LT and be included in the indications for LT for CHC. This study evaluated the outcomes of patients showing combined HCC-intrahepatic cholangiocarcinoma in explant pathology.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/da/4b/hf-4-097.PMC10564256.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41214611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective/preventive effects of quercetin against cyclophosphamide-induced hepatic inflammation, apoptosis and fibrosis in rats.","authors":"Sibel Turedi","doi":"10.14744/hf.2023.2023.0026","DOIUrl":"10.14744/hf.2023.2023.0026","url":null,"abstract":"<p><strong>Background and aim: </strong>The purpose of this study was to investigate the hepatoprotective effects of quercetin, a potent antioxidant, against hepatotoxicity caused by cyclophosphamide (CYC) in the rat liver using histopathological parameters.</p><p><strong>Materials and methods: </strong>Thirty female rats were divided into five groups - control, quercetin (Q), CYC, Q+CYC, and CYC+Q. At the end of the study, the liver tissues were removed and stained with routine histological hematoxylin and eosin, Periodic acid-Schiff, and Masson's trichrome. Caspase-3 (Cas-3), B-cell lymphoma protein 2-associated X (Bax), tumor necrosis factor alpha (TNF-α), and interleukin 1 beta (IL-1β) levels were investigated in immunohistochemically stained liver tissues.</p><p><strong>Results: </strong>Histopathological examination showed that CYC caused impairment and degeneration in the structure of the hepatocyte cordon, necrosis in the periportal space, sinusoidal dilatation (p=0.000), congestion and edema (p=0.000), mononuclear cell infiltration, and increased connective tissue density (p=0.000). Cas-3, Bax, TNF-α, and IL-1β immunoreactivities were significantly higher in the CYC group (for all, p=0.000). Q administration gradually reduced histopathological structural damage and Cas-3, Bax, TNF-α (p=0.000), and IL-1β (p=0.000) intensity in the rat liver.</p><p><strong>Conclusion: </strong>The administration of Q protected the liver tissue against CYC-induced damage, and successfully protected the liver against apoptosis, inflammation, and histopathological changes.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/29/hf-4-135.PMC10564257.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41214615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort.","authors":"Serkan Yaras,&nbsp;Mehmet Demir,&nbsp;Sezgin Barutcu,&nbsp;Abdullah Emre Yildirim,&nbsp;Selim Gurel,&nbsp;Enver Ucbilek,&nbsp;Ilkce Akgun Kurtulmus,&nbsp;Meral Akdogan Kayhan,&nbsp;Sezgin Vatansever,&nbsp;Haydar Adanir,&nbsp;Nilay Danis,&nbsp;Serkan Duman,&nbsp;Ilker Turan,&nbsp;Derya Ari,&nbsp;Sukran Kose,&nbsp;Huseyin Alkim,&nbsp;Muhsin Murat Harputluoglu,&nbsp;Feyza Dilber,&nbsp;Murat Akyildiz,&nbsp;Arif Mansur Cosar,&nbsp;Serdar Durak,&nbsp;Goktug Sirin,&nbsp;Ayse Kefeli,&nbsp;Hale Gokcan,&nbsp;Ufuk Avcioglu,&nbsp;Talat Ayyildiz,&nbsp;Orhan Sezgin,&nbsp;Mesut Akarsu,&nbsp;Dinc Dincer,&nbsp;Fatih Guzelbulut,&nbsp;Fulya Gunsar,&nbsp;Ulus Salih Akarca,&nbsp;Ramazan Idilman","doi":"10.14744/hf.2023.2023.0001","DOIUrl":"10.14744/hf.2023.2023.0001","url":null,"abstract":"<p><strong>Background and aim: </strong>The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC).</p><p><strong>Materials and methods: </strong>Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study.</p><p><strong>Results: </strong>All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per protocol analysis. The SVR12 rates were statistically significant differences between the patients who were i.v. drug users and non-user (88.0% vs. 98.8%, p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p<0.001 and p=0.014, respectively). No severe adverse effect was observed.</p><p><strong>Conclusion: </strong>GLE/PIB is an effective and tolerable treatment in patients with CHC.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a5/90/hf-4-092.PMC10564251.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41214618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and predictors of metabolic-associated fatty liver disease in liver transplant recipients: A cross-sectional prospective study.","authors":"Gupse Adali,&nbsp;Nermin Mutlu Bilgic,&nbsp;Ahmet Emre Kalaman,&nbsp;Oguzhan Ozturk,&nbsp;Kamil Ozdil","doi":"10.14744/hf.2023.2023.0032","DOIUrl":"10.14744/hf.2023.2023.0032","url":null,"abstract":"<p><strong>Background and aim: </strong>Metabolic-associated fatty liver disease (MAFLD) has emerged as a significant global health concern. However, the prevalence and predictors of MAFLD in post-liver transplantation (LT) patients remain uncertain. This study aimed to determine the prevalence and predictors of MAFLD in LT recipients and to assess the effectiveness of controlled attenuation parameter (CAP) values in diagnosing post-transplant MAFLD.</p><p><strong>Materials and methods: </strong>A cross-sectional prospective study was conducted involving 128 adult patients who had undergone LT, and had received liver imaging, and vibration-controlled transient elastography (VCTE). MAFLD was diagnosed on the basis of the presence of liver steatosis detected through imaging and specific metabolic risk abnormalities.</p><p><strong>Results: </strong>The prevalence of MAFLD after LT was 34.4%, with 22.1% categorized as de novo MAFLD, and 12.3% as recurrent MAFLD. Posttransplant diabetes (OR: 4.88; 95% CI 1.30-18.34; p=0.019) and higher CAP values (OR: 1.04; 95% CI 1.02-1.06; p=0000) were identified as independent predictors of post-LT MAFLD. A CAP cutoff value of 270 dB/m exhibited an area under the receiver operating curve of 0.84 in detecting MAFLD.</p><p><strong>Conclusion: </strong>These findings underscore the notable prevalence of MAFLD in liver transplant recipients and suggest the potential utility of VCTE as a non-invasive tool for its detection.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4a/78/hf-4-129.PMC10564255.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41214614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioinformatic analysis of genetic changes CLOCK, BMAL1, CRY1, CRY2, PER1, PER2, PER3, and NPAS2 proteins in HCC patients.","authors":"Durmus Ayan,&nbsp;Ak Cagatay","doi":"10.14744/hf.2023.2023.0009","DOIUrl":"10.14744/hf.2023.2023.0009","url":null,"abstract":"<p><strong>Background and aim: </strong>Genes related to the circadian rhythm control various biological processes. The aim of this study was to comprehensively investigate the mutational and mRNA profile of core circadian rhythm genes in hepatocellular cancer (HCC) samples.</p><p><strong>Materials and methods: </strong>In this study, the gene profile of a total of 369 patients with HCC was examined over the data obtained from the cancer genome atlas database through-cBioPortal. The effects of mutations on protein were examined by scoring the Polymorphism Phenotyping v2, Mutation Assessor, and SIFT-databases. While the association of genes with other genes was determined with the GeneMANIA-database, the association of expression levels in the genes with overall survival (OS) was evaluated with the Kaplan-Meier Plot database.</p><p><strong>Results: </strong>As a result of the analyses, there were a total of 25 mutations. Decreased expression levels of PER1 (1.3e-05), PER3 (p=0.046), and CRY2 (p=1.8e-06) genes were found statistically associated with shorter OS. It was also found that increased expression levels of the PER2 (p=0.045) gene were associated with longer OS, and increased expression levels of the NPAS2 (p=9e-04) gene were associated with shorter OS.</p><p><strong>Conclusion: </strong>In particular, changes in the PER1, PER2, CRY2, and NPAS2 genes may provide possible molecular targets in chemotherapy and immunotherapy for HCC patients.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/82/hf-4-108.PMC10564247.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41214609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should dermatologists care about hepatic fibrosis and steatosis? Psoriasis first, hidradenitis suppurativa second.","authors":"Enzo Emanuele, Piercarlo Minoretti","doi":"10.14744/hf.2023.2023.0029","DOIUrl":"10.14744/hf.2023.2023.0029","url":null,"abstract":"","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/41/hf-4-150.PMC10564246.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41214617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronotype preference, sleep quality, and night-eating behaviors in patients with metabolic dysfunction-associated steatotic liver disease: Assessing the relationship with disease severity and fibrosis.","authors":"Ayse Sakalli Kani, Ahmet Ozercan, Haluk Tarik Kani, Fatih Eren, Kemal Sayar, Yusuf Yilmaz","doi":"10.14744/hf.2023.2023.0034","DOIUrl":"10.14744/hf.2023.2023.0034","url":null,"abstract":"<p><strong>Background and aim: </strong>Our primary objective is to examine the variance in chronotype, night-eating patterns, and sleep quality in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease. In addition, we aim to establish a correlation between these variables and the severity of the disease and fibrosis.</p><p><strong>Materials and methods: </strong>Patients who were following up with biopsy-proven metabolic dysfunction associated steatotic liver disease (MASLD) were included in the study. Histologically severe disease is characterized by a Steatosis, Activity, and Fibrosis activity score of ≥3 or the presence of advanced fibrosis (≥F3). Participants who met the inclusion criteria were given the Morningness and Evening Questionnaire (MEQ), the Pittsburgh Sleep Quality Index, and the Night Eating Questionnaire to complete.</p><p><strong>Results: </strong>A total of 93 patients were included in this study. According to the MEQ, 48 patients were morning type (51.6%), and 42 (45.2%) were neither type. Sleep quality was determined to be inferior in the non-morningness group (p=0.002). A significantly higher proportion of patients with nocturnal eating syndrome had a non-morningness chronotype preference (n=22, 23.7%), compared to those with a morningness chronotype (n=9, 9.7%) (p=0.001). In the multivariate analysis, both age and poor sleep quality had significant impacts on advanced fibrosis, with odds ratios of 1.11 and 3.81, respectively.</p><p><strong>Conclusion: </strong>Despite the non-morningness chronotype demonstrating poorer sleep quality and a higher prevalence of night-eating behavior, our findings revealed no statistically significant differences in terms of sleep quality, nocturnal eating habits, or chronotype preferences among patients with varying degrees of MASLD severity. On the other hand, advanced fibrosis was significantly impacted by poor sleep quality.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0f/e9/hf-4-123.PMC10564252.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41214610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The heated debate over NAFLD renaming: An ongoing saga.","authors":"Yusuf Yilmaz","doi":"10.14744/hf.2023.2023.0044","DOIUrl":"10.14744/hf.2023.2023.0044","url":null,"abstract":"","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/b5/hf-4-089.PMC10564248.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41214619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}